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Abstract 
 
Human immunodeficiency virus (HIV) infection may be 
associated with renal impairment since about 0.4% of 
all HIV-positive patients develop end-stage renal disease. 
The share of patients with HIV infection in hemodialysis 
centers throughout the world ranges from 0.3% to as 
high as 38%. In Croatia, renal replacement therapy was 
needed by 1% of all the HIV-positive patients from 1985 
until the end of 2014. Healthcare professionals (HP) 
should be aware of the risks of occupational exposure 
to blood-borne infections in their daily work. Performing 
dialysis in HIV-positive patients increases the risk of 
exposure to HIV during the extracorporeal circulation of 
the infected blood. However, post-exposure prophylaxis 
(PEP) with effective antiretroviral drugs significantly 
reduces the risk of infection after occupational exposure. 
On behalf of the Croatian Society of Nephrology, Dialysis 
and Transplantation, the authors of this paper have pro-
posed recommendations for the management of HIV-
positive patients on dialysis, which aim to prevent the 
transmission of HIV among patients and HPs. The 
important recommendations include the following:  
1. when the need arises, it is necessary to provide 
HIV-positive patients with dialysis in the vicinity 
of their place of residence.  
2. HIV-positive patients should be dialyzed with a 
separate hemodialysis machine in an isolated area. 
Alternatively, they can be dialyzed in an area for 
the hemodialysis of HCV-positive and/or HBV-
positive patients.  
3. Specialized and trained personnel should be provi-
ded during the hemodialysis procedure, together with 
strict compliance with the standard precautions for 
the prevention of blood-borne infections.  
4. There should be a good and prompt cooperation 
with the National Referral Center for HIV infection. 
 
Keywords: human immunodeficiency virus, HIV,  
dialysis, recommendations, blood transmitted infection, 
exposure, prevention  
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Introduction 
 
When the disease caused by the human immunodeficien-
cy virus (HIV) is left untreated, it generally progresses 
inexorably in all infected persons, from asymptomatic 
infection to the condition of complete destruction of 
the immune system, resulting in acquired immunodefi-
ciency syndrome (AIDS) [1]. However, today, thanks 
to antiretroviral therapy (ART), HIV infection has be-
come a chronic condition that can be successfully 
managed long-term [2-4]. Some observational studies 
have suggested that persons infected with HIV can live 
nearly as long as non-infected persons [5,6].  
Owing to the prolonged life expectancy of persons 
infected with HIV, there has been an increase in the 
chronic diseases and complications associated with the 
treatment of HIV and the drugs used to manage HIV 
diseases, including acute and/or chronic renal disease 
[7]. In HIV-infected persons, kidney damage may occur 
as a result of the direct effects of the virus, such as 
HIV-associated nephropathy (HIVAN), as well as the 
indirect effects of HIV, including complications of 
immunodeficiency caused by HIV, secondary (oppor-
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tunistic) infections and side effects from the treatment 
of these conditions, i.e., nephrotoxic drugs. Chronic renal 
failure is associated with common risk factors, such as 
age, hypertension and diabetes, but also with certain 
antiretroviral drugs (tenofovir, indinavir and others) [8].  
 
Epidemiology of Renal Failure in Persons Infected 
with HIV 
 
Croatia, with an annual rate of new HIV diagnoses of  
10-20/1,000,000 inhabitants, is among the countries with 
the lowest prevalence rates. According to the HIV/ AIDS 
Registry of the Croatian National Institute of Public 
Health, from 1985, when the first cases of HIV infection 
were recorded in Croatia, to the end of 2014, a total of 
1,194 HIV-positive individuals have been registered.  
Possible factors responsible for an increased risk of deve-
loping acute/chronic renal failure (ARF/CRF) are advan-
ced age, female sex, diabetes, hypertension, intravenous 
drug abuse, certain coinfections (hepatitis B virus, hepatitis 
C virus), low CD4 T-lymphocyte count, the use of some 
antiretroviral drugs, a history of renal impairment and 
high HIV viral load. Numerous studies have already de-
monstrated that the use of antiretroviral drugs and supp-
ression of the viral load can improve kidney function and 
reduce proteinuria, thereby indicating that HIV has a 
nephrotoxic effect. This is particularly evident in Afro-
Americans, for whom the risk for CRF is nearly three 
times higher than for Caucasians [9].  
In a large study involving over 35,000 patients, 0.4% 
of them developed stage 4 or 5 renal failure (GFR <30 
ml/min or dialysis or transplant), with an incidence rate 
of 0.67/1,000 person years of follow-up (PYFU) [8]. 
In a cross-sectional multicenter EuroSIDA survey, the 
prevalence of end-stage renal disease (ESRD) was 0.5% 
[10], and an observational cohort study conducted in 
Great Britain showed a 3.8-fold increase in ESRD among 
the black HIV-positive patients in the cohort during the 
12-year study period [11].  
The percentage of patients infected with HIV in dialysis 
centers around the world ranges from 0.3% to as high 
as 38% [12]. From 1985 to 1999 the percentage of dialy-
sis centers providing care to HIV-positive patients in 
the United States increased from 11% to 39% [13]. 
 
Methods for Treating Chronic Renal Failure in 
HIV-infected Patients  
 
For HIV-infected patients who develop severe renal 
impairment, whether acute or chronic, replacement of 
renal function is necessary. They can be treated with 
hemodialysis (HD), peritoneal dialysis (PD), and may 
be candidates for kidney transplantation [12-14]. In the 
aforementioned EuroSIDA survey, out of 122 patients 
with ESRD, 96 received dialysis and 26 renal transplant. 
The most frequent causes of ESRD were HIV-associated 
nephropathy and other glomerulonephritis [10]. The ad-
vantages and disadvantages of each form of dialysis in 
HIV-infected patients are presented in Table 1. 
  
Table 1. Advantages and disadvantages of dialysis in patients with HIV-infection [adapted from 
11,14,15] 
METHOD ADVANTAGES DISADVANTAGES 
HEMODIALYSIS 
- Transmission of the virus by dialysis 
machines has not been confirmed* 
- Higher risk of HCV-infection for 
patients 
- Lowering of the viral load in the 
blood during the procedure 
- Higher frequency of contacts with 
patients’ blood, higher risk of 
infection transmission to personnel 
 - Higher costs 
PERITONEAL 
DIALYSIS 
- Less risk of infection transmission to 
personnel 
- Possibility of viral replication in 
the dialysate** 
- Lower costs - Higher incidence of peritonitis 
(due to opportunistic 
microorganisms) 
*The size of the HIV virion is about 105 nm and the pores of the dialyzer are 1-7 nm. Viral RNA is not 
detectable in the dialysate. 
**Peritoneal dialysate is less contagious than blood but the virus can replicate in the dialysate: up to 7 
days at room temperature and up to 2 days in empty lines. 
 
Additional shortcomings of PD are the loss of protein 
into the dialysate in already asthenic patients, cognitive 
motor dysfunction in advanced HIV diseases and redu-
ced patient compliance [14,15]. Priority should be given 
to HD and transplantation when possible. The observa-
tional cohort study conducted in Great Britain showed 
that the 5-year survival of patients infected with HIV 
who had received transplants was similar to that of pa-
tients infected with HIV who were receiving dialysis 
and on the transplant list (85% and 89%, respectively). 
The good transplant results of this group of patients  
should be placed in the context of a young patient po-
pulation, relatively short period of monitoring and, most 
importantly, the exclusion of patients with contraindica-
tions for transplantation, among whom survival is sig-
nificantly limited. Patients infected with HIV have a 
markedly higher rate of kidney rejection in the first post-
transplant year in comparison to transplant patients not 
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infected with HIV: 31-48% vs. 12-24%, probably asso-
ciated with HIV-modulated immune response and less 
exposure to immunosuppressants, together with highly 
active antiretroviral therapy [11]. 
 
Prevention of HIV Transmission in Dialysis Centers 
 
Healthcare personnel should be aware of the risk of occu-
pational exposure to blood-borne pathogens in their daily 
duties. Therefore, they should be expected to fully comply 
with the standard precautions to prevent exposure to blood, 
other bodily fluids and tissues potentially containing 
HIV and other blood-borne pathogens [16,17]. 
Administration of dialysis to patients infected with HIV 
increases the risk of sharps injuries, particularly needles-
ticks. The risk of seroconversion after a needlestick in-
volving exposure to the blood of a HIV-positive patient 
is 0.3%, while the risks for hepatitis B and C are conside-
rably higher, 2% for HCV and 6-30% for HBV [16,18-20]. 
HIV, like HBV and HCV, does not pass through intact 
skin and the airborne transmission of this virus has not 
been confirmed. Contacts via broken skin, blood splashes 
on the mucous membranes and other forms of mucocuta-
neous incidents rarely result in seroconversion and infec-
tion [16]. In a retrospective study by Cardo et al. [19], 
the risk factors increasing the transmission of HIV in-
fection after percutaneous exposure were deep injury, 
injury with a device that was visibly contaminated with 
blood, injury with a device that had previously been 
placed in the source patient’s vein and the death of the 
source patient two months after the percutaneous inci-
dent. These factors are probably surrogate markers of 
viral inoculum. Although low titer viremia may mean 
lower inoculum, it does not entirely exclude the possibili-
ty of the transmission of HIV infection because the viral 
load does not include the intracellular HIV. Transmission 
of HIV infection from source patients with undetectable 
HIV levels in the blood has been documented [20]. 
The first case of the transmission of HIV infection from a 
patient to a healthcare worker occurred in 1984 [21]. In 
1987, the US Centers for Disease Control and Prevention 
(CDC) issued Recommendations for Prevention of HIV 
Transmission in Healthcare Settings and for other blood-
borne pathogens, in which the concept of universal pre-
cautions was introduced [22]. According to these reco-
mmendations, the blood and bodily fluids of every pa-
tient are potentially infectious and should be treated as 
such. The CDC recommends compliance with the reco-
mmendations for control and prevention of blood-borne 
infections issued by the United States Occupational Safety 
and Health Administration (OSHA). These recommenda-
tions are regularly updated and revised according to in-
formation from recent studies and are readily available 
in printed or electronic form via the CDC website [22, 
23]. From 1984 to 1999, 57 healthcare workers in the 
United States acquired HIV infection occupationally, 
most often from needlestick incidents (84%). From 1999 
to the end of 2013, owing to compliance with the CDC 
recommendations, only one healthcare worker acquired 
HIV infection occupationally (a laboratory technician 
from a needle puncture while working with a live HIV 
culture) [24]. In dialysis units, there have been no repo-
rted cases of the transmission of HIV among patients in 
the United States but cases were reported in Argentina 
(two dialysis centers), Columbia and Egypt [25]. Post-
exposure prophylaxis (PEP) significantly reduces the 
risk of infection and is, therefore, justified whenever 
possible [19,20,26]. 
Experiences of Other Countries in the Management 
of Kidney Failure in Persons Infected with HIV  
 
The international guidelines are largely based on the re-
commendations of the CDC, with certain particularities 
related to the dialysis centers, equipment and type of 
dialyzer. 
The European Best Practice Guidelines for the Preven-
tion and Management of HBV, HCV and HIV in Hemo-
dialysis Patients recommend the suitable implementation 
of the standard precautions for protection from the trans-
mission of infectious agents, which has achieved a very 
low risk of infection transmission. It is necessary to 
screen for the presence of individual pathogens (HBV, 
HCV and HIV) in all patients included in a dialysis prog-
ram for the first time or when are transferred from other 
dialysis centers, having obtained the patients’ prior in-
formed consent. The isolation of patients infected with 
HIV in a separate area and the use of special dialysis 
machines for them are not recommended. The principles 
for the prevention of the transmission of HBV infection 
are also sufficient for the prevention of the transmi-
ssion of HIV [27]. 
The most common errors in the protocol for infection 
control that can lead to the transmission of infection are 
the reuse of dialyzers, blood lines and the same needles 
for different patients; the use of contaminated multidose 
heparin vials and the use of ineffective disinfectant 
(benzalkonium chloride) [28]. 
The recommendations of the Infectious Diseases Society 
of America state that dialysis is safe for healthcare wor-
kers and patients if the recommendations of the CDC 
for the prevention and control of infection are strictly 
followed. Vascular access for dialysis (the placement of 
endovenous catheters and the creation of arteriovenous 
fistulae) should be provided for all patients, including 
those infected with HIV [29]. 
On the other hand, in some countries, such as the Repub-
lic of South Africa, in addition to the implementation 
of the standard precautions and annual screening for 
the causes of infectious diseases in all dialysis patients, it 
is recommended that patients infected with HIV should 
be dialyzed in separate areas or rooms, although it is 
not insisted on the use of dedicated machines [30]. 
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Croatian Recommendations for the Dialysis of 
HIV-Positive Patients  
 
At the meeting of the Board of the Croatian Society for 
Nephrology, Dialysis and Transplantation (HDNDT) on 
January 25, 2013, it was decided to prepare Recommen-
dations for the Prevention of HIV Infection in Patients on 
Dialysis and Healthcare Workers, in cooperation with 
infectious disease specialists from the Dr. Fran Miha-
ljevic University Hospital for Infectious Diseases in 
Zagreb, the Croatian Referral Center for the Diagnosis 
and Treatment of HIV Infection. The first version of the 
recommendations was published on the website of the 
Croatian Society for Nephrology, Dialysis and Transplan-
tation in April 2014, for the purpose of public debate.  
Until now, HIV-positive patients have been receiving 
acute dialysis at the Dr. Fran Mihaljevic University 
Hospital for Infectious Diseases, University Hospital 
Center in Zagreb, and the University Hospital Center 
in Split, while chronic hemodialysis, in addition to the 
Dr. Fran Mihaljevic University Hospital for Infectious 
Diseases and University Hospital Center in Zagreb (since 
2003) is also provided at the Sibenik General Hospital 
(2013-2015). It may be expected that the need will 
arise to provide dialysis to patients with HIV in other 
centers. Therefore, the Croatian Society for Nephrology, 
Dialysis and Transplantation has proposed Recommenda-
tions for the Dialysis of HIV-Positive Patients, with the 
goal of preventing the transmission of HIV infection 
among patients and healthcare personnel.  
Based on current knowledge, literature and the authors’ 
experience, on behalf of the Croatian Society for Nephro-
logy, Dialysis and Transplantation, recommendations 
have been made for the dialysis of HIV-positive patients, 
based on the level and degree of evidence in the guide-
lines presented/cited in Tables 2 and 3 [31]. 
  
Table 2. Level of Evidence in the Guidelines [adapted from 31] 
 IMPACT OF THE GUIDELINES 
LEVEL OF 
IMPACT 
ON PATIENTS ON PHYSICIANS ON DECISIONS 
LEVEL 1 
We recommend 
The majority of patients would 
like to receive the 
recommended therapy. 
The recommendations should 
be applied to the majority of 
patients. 
The guidelines can be the basis 
for the recommended 
application. 
LEVEL 2 
We advise 
A large number of patients 
would like to receive the 
recommended therapy. 
Various options can be 
applied; an individualized 
approach is required. 
The guidelines should be 
discussed before the 
recommendations are applied. 
 
Table 3. Level of Evidence in the Guidelines [adapted from 31] 
 IMPACT OF THE GUIDELINES 
LEVEL OF 
IMPACT 
QUALITY OF 
EVIDENCE 
SIGNIFICANCE 
A High 
We are convinced that the actual impact is very 
close to that of the estimated impact. 
B Medium 
The actual impact is close to the estimated 
impact but there are possible discrepancies. 
C Low 
The actual impact could be different from the 
estimated impact. 
D Very Low 
The estimated impact is uncertain, probably far 
from the actual impact. 
  
Recommendations 
 
 When the need arises, it is necessary to provide 
HIV-positive patient with dialysis in the vicinity 
of his/her place of residence (1A). 
 
Commentary 
 
 Renal function is impaired in over 30% of per-
sons infected with HIV [29].  
 HIV-positive persons who exhibit the following 
should be referred to a nephrologist:  
- a significant decrease in the glomerular filtration 
rate (GFR), >25%, compared to the previous value,  
- GFR <60 ml/min/1.73 m
2
 with albuminuria >300 
mg/24 hours, hematuria, elevated arterial pressure 
and 
- GFR <30 ml/min/1.73 m
2
 (1C). 
 This group of patients should be provided with 
vascular access for hemodialysis, optimally a na-
tive arteriovenous fistula [32] (1B). 
 It is necessary to determine the viral status of all 
patients included in a hemodialysis program and 
all patients transferred from other centers for he-
modialysis, including HBsAg, anti-HBs, anti-HBc, 
HBeAg, anti-HBe, anti-HCV, anti-HIV, and HBV 
DNA screening for all anti-HBc total (IgG/IgM) 
and/or anti-HBe positive patients (1A). 
 The viral status of all patients on hemodialysis 
should be checked every six months (1C). 
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Commentary on recommendations 2 and 3  
 
 It is necessary to diagnose persons infected with 
HIV early, in order to initiate antiretroviral therapy 
and reduce the incidence of opportunistic infections. 
Early ART would also lower the risk of HIV 
transmission and HIV-associated non-AIDS (HANA) 
conditions as it lowers the risk of opportunistic 
infections. However, when the CDC guidelines 
are strictly followed, the risk of HIV transmission 
is practically negligible [27]. Therefore, the reco-
mmendation of the European Renal Best Practice 
is to determine anti-HIV at the beginning of dialy-
sis treatment and when patients are to be trans-
ferred from one to another dialysis center, although 
this is not necessary every six months [33,34]. The 
Croatian Society for Nephrology, Dialysis and Trans-
plantation considers that this opinion by the ERBP 
working group on Kidney Disease: Improving Global 
Outcomes (KDIGO) guidelines for preventing infec-
tion transmission in hemodialysis units should be 
adapted to Croatian conditions. Since we believe 
that there is room for improvement in the imple-
mentation of CDC guidelines in dialysis centers 
and reduction of nosocomial transmission, and are 
prompted by our own experiences with a large 
proportion of HCV-positive patients 15 years ago, 
we recommend the monitoring of the viral status 
of hemodialysis patients every six months.  
 In HIV-positive patients, it is necessary to quantify 
the viral load (HIV RNA) every six months or more 
often, as needed (1C).  
 
Commentary 
 
 HIV viremia should be determined once a year 
according to the infectious diseases recommendations 
(1A). However, due to the increased risk of noso-
comial transmission of HIV owing to extracorporeal 
circulation during the hemodialysis procedure, we 
believe that it is necessary to determine the HIV 
viremia of HIV-positive patients on hemodialysis 
every six months. In cases of patient noncompliance 
and suspected irregular intake of therapy (that 
increases the possibility of developing antiretroviral-
drug-resistant HIV), which can result in increased 
viremia and contagiousness, HIV viremia should 
be determined immediately.  
 HIV-positive patients should be dialyzed with a 
separate hemodialysis machine (in addition to pro-
viding a backup machine in the event of breakdown) 
in an isolated area. Alternatively, they can be dialy-
zed in an area for hemodialysis of HCV-positive 
and/or HBV-positive patients (1B). 
 
Commentary 
 
 Although the KDIGO guidelines, opinion of the 
ERBP, and recommendations of the Infectious Disease 
Society of America do not endorse separate hemo-
dialysis machines for HIV-positive patients (Level 
B of evidence for separate machines, Level C for an 
isolated area [27-29]), cases of the transmission 
of HIV among patients in the dialysis centers of 
developing countries have been recorded due to 
failure to comply with the CDC guidelines [35,36]. 
Therefore, our recommendation is that the dialysis 
of HIV-positive patients should be conducted using 
separate dialysis machines in isolated areas. 
 In the case of coinfection with HBV, hemodialysis 
should be performed in a HBV-positive area, and 
in the case of coinfection with HCV, in a HCV-
positive area. 
 HIV-positive patients should be vaccinated against 
HBV and HAV (1A). 
 Trained personnel should be provided during the 
hemodialysis procedure (medical technician/nurse, 
cleaning staff), together with strict compliance with 
the general measures for the prevention of blood-
borne infections (1A). 
 
Commentary 
 
   The standard precautions for protection from pa-
thogens are based on the principle that blood, 
bodily fluids, excretions (except perspiration) and 
mucous membranes can contain transmissible infec-
tious agents. These precautions are designed to 
protect patients and healthcare personnel, and in-
clude hand hygiene, the use of adequate protection 
(gloves, masks, goggles and aseptic techniques in 
order to reduce patient exposure to microorganisms), 
procedures for sharps/infectious waste, spilled blood 
and bedding; routine cleaning of the hospital en-
vironment and the immunization of personnel. 
These measures should be especially carefully 
implemented in dialysis centers, owing to extracor-
poreal circulation during the HD procedure (1C). 
 Nevertheless, we cannot be certain that all these 
measures will be implemented in their entirety [37].  
 Acute hemodialysis should be performed in separate 
areas of intensive care units on continuous dialysis/ 
hemofiltration machines (with the dialysis solution 
and dialysate in a closed system) or hemodialysis 
machines with a reservoir containing prepared so-
lution for hemodialysis (Genius) (1B). 
 Blood and other specimens from HIV-positive 
patients in institutions, the Department of Public 
Health or other public health institutions should 
be transported in leak-proof PVC containers with 
well fitted lids and labeled "B20". Specimens sent 
outside an institution should be conveyed by me-
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dical transport, not by public transportation or mail, 
in additional packaging (small wooden boxes).  
 There should be good and prompt cooperation with 
the National Referral Center of the Ministry of 
Health for the Diagnosis and Treatment of HIV 
Infection (contact telephone 2826 227 or 2826 206, 
e-mail: bfm@bfm.hr) for rapid diagnosis and pro-
fessional assistance in case PEP is needed. In the 
event of a needlestick involving the blood of a 
HIV-positive patient, PEP should begin as soon as 
possible, preferably within 24 hours, but no later 
than 72 hours after the incident, and continue for 
four weeks. Highly active antiretroviral therapy 
(HAART) should be adjusted according to the 
therapy being received by the HIV-positive patient 
in consultation with the attending infectious disease 
specialist at the Dr. Fran Mihaljevic University 
Hospital for Infectious Diseases [17] (1A).  
 
Conclusion 
 
HIV is an important public health problem, which poses 
challenges to experts and healthcare personnel in cases 
of renal failure and the management of renal replacement 
therapy. The majority of these patients are on hemodialy-
sis, while a significantly smaller number are on perito-
neal dialysis or have received transplants. Healthcare 
personnel should be aware of the risk of occupational 
exposure to blood-borne infection in their daily work, 
and are expected to comply with all the measures that 
can prevent their exposure to blood, other bodily fluids 
and tissues that may contain potentially blood-borne 
infectious pathogens. The dialysis procedure for HIV-
positive patients characterized by the extracorporeal 
circulation of blood presents a risk for inoculating the 
virus in the event of a needlestick incident, although 
the seroconversion risk after needlestick injuries is 0.3%, 
while the risks of seroconversion for hepatitis B and C 
are significantly higher: 2% for HCV and as high as 6-
30% for HBV. Postexposure prophylaxis with antiret-
roviral therapy for four weeks significantly lowers the 
risk of seroconversion even further.  
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